Figure 6.

Clinical impact of dynamic profiling of immune features in pre-treatment and on-treatment patients

(A) Alterations of checkpoint expression between on-treatment and pre-treatment samples in benefit group (upper panel) and non-benefit group (bottom panel) in six ICB treatment datasets. Text label (red: stimulatory checkpoint; blue: inhibitory checkpoints). Black box of dots indicates the significant difference (FDR < 0.2).

(B and C) The differential expression of inhibitory and stimulatory immune checkpoints between benefit group and non-benefit group in pre-treatment (B) and on-treatment (C). Black circle of dots indicates significant difference (FDR < 0.2). Benefit group denotes patients with PR/CR and SD under ICB treatment, and non-benefit group denotes patients with PD under ICB treatment.

(D) The alteration of relative abundance of 28 immune cell populations between on-treatment and pre-treatment samples in benefit group (upper panel) and non-benefit group (bottom panel) in five ICB treatment datasets. Black box of dots indicates the significant difference (FDR < 0.2).

(E and F) Difference of relative abundance of immune cell populations between benefit group and non-benefit group in pre-treatment (E) and on-treatment (F). Black circle of dots indicates the significant difference (FDR < 0.2). Statistical analysis is performed by two-sided Student's t test.